BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017;177:72-83. [PMID: 27864925 DOI: 10.1111/bjd.15193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Skalkou A, Manoli SM, Sachinidis A, Ntouros V, Petidis K, Pagkopoulou E, Vakirlis E, Pyrpasopoulou A, Dimitroulas T. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int 2018;38:161-7. [PMID: 29075910 DOI: 10.1007/s00296-017-3861-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-Induced Pyoderma Gangrenosum: A Review. Am J Clin Dermatol 2018;19:67-77. [PMID: 28624960 DOI: 10.1007/s40257-017-0308-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
3 Sevimli Dikicier B. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report. Adv Skin Wound Care 2019;32:427-9. [PMID: 31408027 DOI: 10.1097/01.ASW.0000577128.03996.95] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol 2020;83:1130-43. [PMID: 32360716 DOI: 10.1016/j.jaad.2020.04.105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
5 Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019;180:615-20. [PMID: 29388188 DOI: 10.1111/bjd.16401] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
6 Tunçez Akyürek F, Akyurek M, Zekey E, Can I, Saylam Kurtipek G. Pyoderma gangrenosum with thymoma and myasthenia gravis: A case report. J Cosmet Dermatol 2021;20:943-6. [PMID: 32920928 DOI: 10.1111/jocd.13717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020;17:1255-65. [PMID: 32378319 DOI: 10.1111/iwj.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ, Aragón I, Segura S, Beato C, Botella R. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2019;21:556-71. [PMID: 30284232 DOI: 10.1007/s12094-018-1953-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
9 Haag CK, Nutan F, Cyrus JW, Satpathy J, Shinkai K, Ortega Loayza AG. Pyoderma gangrenosum misdiagnosis resulting in amputation: A review. J Trauma Acute Care Surg 2019;86:307-13. [DOI: 10.1097/ta.0000000000002096] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. European Journal of Preventive Cardiology 2021;28:983-9. [DOI: 10.1177/2047487320915663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Haber R, Dib N, El Gemayel M, Makhlouf M. Paradoxical neutrophilic dermatosis induced by biologics and immunosuppressive drugs: A systematic review. J Am Acad Dermatol 2021:S0190-9622(21)00360-1. [PMID: 33607180 DOI: 10.1016/j.jaad.2021.02.035] [Reference Citation Analysis]
12 Welborn ME, Kubicki SL, Patel AB. Pyoderma Gangrenosum Following Initiation of Immune Checkpoint Inhibitor Therapy. Journal of Immunotherapy and Precision Oncology 2018;1:82-4. [DOI: 10.4103/jipo.jipo_11_18] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Noronha M, Arora S, Pai K, Sathish Pai B, Jindal A. A case of pyoderma gangrenosum induced by insulin. Int Wound J 2019;16:1239-42. [PMID: 31353778 DOI: 10.1111/iwj.13170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018;14:225-33. [PMID: 29406827 DOI: 10.1080/1744666X.2018.1438269] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 13.7] [Reference Citation Analysis]
15 Mogle BT, Seabury RW, Jennings S, Cwikla GM. Severe neutrophilic dermatosis following submental deoxycholic acid administration. Clin Toxicol (Phila) 2017;55:681. [PMID: 28394637 DOI: 10.1080/15563650.2017.1306071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ortega-Loayza AG, Nugent WH, Lucero OM, Washington SL, Nunley JR, Walsh SW. Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. Br J Dermatol 2018;178:e35-6. [PMID: 28734003 DOI: 10.1111/bjd.15837] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
17 Sehgal R, Resnick JM, Al-Hilli A, Mehta N, Conway T, Stratman EJ. Nasal septal and mucosal disease associated with pyoderma gangrenosum in a cocaine user. JAAD Case Rep 2017;3:284-7. [PMID: 28702496 DOI: 10.1016/j.jdcr.2017.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]